Use of Lifetech™ Konar-MF, a device for both perimembranous and muscular ventricular septal defects: A multicentre study

Abstract Background The objective of this study was to evaluate the safety and efficacy of transcatheter closure of ventricular septal defects (VSD) using the LifeTech™ multifunctional occluder device (MF-Konar). Methods Clinical features and demographic characteristics and follow-up findings were evaluated retrospectively from three centers. Results MF-Konar was used in 98 patients. The median age and weight of the patients were 3.8 years (range 5.4 months–50 years) and 15.3 kg (range 5.5–80 kg), respectively. The mean fluoroscopy time was 13.7 ± 8.2 min (range 3.4–42.6 min). Procedural success was obtained for 96 out of 98 patients (98%). In 54 out of 98 patients, closure was performed via the antegrade route. Major complications occurred in four patients (embolization in two, complete heart block in one, and device dislocation needing surgical treatment in one). All of the complications were treated successfully, and there was no mortality. Mild residual flow in eight patients (8%), new onset tricuspid valve insufficiency in one (moderate), and new onset aortic valve insufficiency in one (mild) were observed during a mean follow-up duration of 224 ± 149 (10–515) days. Minor rhythm disturbances were observed in eight patients. Conclusions Transcatheter closure of VSDs in selected patients using the LifeTech MF-Konar device seems effective. Its advantages are softer design, use of both an antegrade and retrograde approach, and an advanced smaller delivery system. Increasing the number of usage and the experience will provide more accurate data and low complication rates.